Brokers Offer Predictions for C4 Therapeutics FY2030 Earnings

C4 Therapeutics, Inc. (NASDAQ:CCCC) – Stock analysts at Brookline Capital Management issued their FY2030 earnings per share (EPS) estimates for C4 Therapeutics in a report issued on Monday, January 5th. Brookline Capital Management analyst L. Cann anticipates that the company will post earnings of $40.97 per share for the year. The consensus estimate for C4 Therapeutics’ current full-year earnings is ($1.52) per share.

C4 Therapeutics (NASDAQ:CCCC) last released its quarterly earnings results on Thursday, November 6th. The company reported ($0.44) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.47) by $0.03. C4 Therapeutics had a negative return on equity of 64.40% and a negative net margin of 395.51%.The company had revenue of $11.23 million during the quarter, compared to the consensus estimate of $6.28 million.

A number of other equities analysts have also commented on CCCC. TD Cowen initiated coverage on shares of C4 Therapeutics in a research report on Tuesday, December 2nd. They issued a “buy” rating on the stock. Cowen initiated coverage on shares of C4 Therapeutics in a research note on Tuesday, December 2nd. They issued a “buy” rating on the stock. Stephens reissued an “overweight” rating and set a $6.00 target price on shares of C4 Therapeutics in a research report on Monday, September 22nd. Barclays decreased their price target on shares of C4 Therapeutics from $10.00 to $5.00 and set an “overweight” rating for the company in a report on Wednesday, December 17th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of C4 Therapeutics in a research note on Wednesday, October 8th. Six equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $7.25.

C4 Therapeutics Stock Performance

CCCC opened at $2.03 on Tuesday. The business has a 50 day moving average price of $2.35 and a 200 day moving average price of $2.33. C4 Therapeutics has a twelve month low of $1.09 and a twelve month high of $4.22. The firm has a market cap of $196.73 million, a P/E ratio of -1.22 and a beta of 2.93.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the stock. Zacks Investment Management acquired a new position in shares of C4 Therapeutics during the third quarter valued at about $29,000. Dynamic Technology Lab Private Ltd acquired a new position in C4 Therapeutics in the 2nd quarter valued at approximately $31,000. Savant Capital LLC acquired a new position in C4 Therapeutics in the 2nd quarter valued at approximately $38,000. Catalyst Funds Management Pty Ltd bought a new stake in shares of C4 Therapeutics in the 2nd quarter worth approximately $40,000. Finally, Crestwood Advisors Group LLC acquired a new stake in shares of C4 Therapeutics during the 2nd quarter worth approximately $41,000. Institutional investors own 78.81% of the company’s stock.

About C4 Therapeutics

C4 Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted protein degraders. Utilizing its proprietary Controlled Inducible Degradation (CiD) platform, the company seeks to eliminate disease-causing proteins by harnessing the body’s natural protein disposal machinery. This approach aims to address a wide range of oncology and immuno-oncology indications by targeting proteins that have historically been difficult to inhibit with traditional small molecules or antibodies.

The company’s pipeline includes multiple small-molecule degrader candidates advancing through preclinical and clinical stages.